By entering this site, you acknowledge that all products and information are provided for research purposes only and are not intended for human consumption or medical use.
You must be 21 years of age or older to use this website.
Each vial ships with structural data and lot identifiers for the compound, plus a Certificate of Analysis documenting purity and identity. Ready for the bench. Synthesized via solid-phase peptide synthesis (SPPS), purified by reverse-phase HPLC, verified by mass spectrometry, and tested for sterility and endotoxin load. Every spec is documented on the signed Certificate of Analysis that ships with your vial.
Retatrutide is a 39-amino acid synthetic peptide that acts as a triple agonist at glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors.
The triple receptor agonism of retatrutide adds hepatic glucagon receptor activation to the incretin-based effects of dual GIP/GLP-1 agonists. Published research has examined hepatic fat oxidation, resting metabolic rate, and energy expenditure pathways associated with this triple-agonist mechanism in preclinical models.
This product is for laboratory research use only. Not for human administration. Not intended to diagnose, treat, cure, or prevent any disease.
Jastreboff AM, et al. · N Engl J Med
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
PubMed · PubMed · 37366317Rosenstock J, et al. · Lancet
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active controlled phase 2 trial
PubMed · PubMed · 3736630210mg / single compound
10mg / single compound
10mg / single compound
30-day money back · Free shipping over $150 · 2-day shipping
[search_result]
Frequently Bought Together